Skip to main content

Advertisement

SpringerLink
Log in

The reactivation time in the treatment of AMD: a forgotten key parameter?

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Objective

Summarize and compare the available evidence on the reactivation times in patients with age-related macular degeneration treated with Ranibizumab (RNB).

Method

Systematic review of studies that reported the reactivation time of patients (direct method) or the number of injections received in a certain period of follow-up (indirect method).

Results

Only 18 of 89 selected studies reported the average reactivation time of patients in a manifest form, without the need of any calculation. The average calculated, weighted reactivation time was 101.8 days with the direct method and 99.8 days in the indirect method (84 studies included). With both methods, it was found that the average reactivation time of the RCTs was between 2 and 3 weeks less than the average time identified in the observational studies. These differences are also reflected in the clinical results, there being a correlation between the number of doses received and the change in BCVA. The analysis of 11 comparative studies showed a difference in reactivation times between patients treated with RNB or Bevacizumab (BVZ).

Conclusion

There are few direct studies of reactivation time, but calculation from the PRN dose number turns out to be a good approximation for retrospective study of the variable. The use of the PRN, with criteria not based on optical coherence tomography scans, delays the application of doses between 2 or 3 weeks, and patients suffer loss of clinical benefits. RNB enables patients to receive less injections than BVZ throughout treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82(11):844–851

    PubMed  PubMed Central  Google Scholar 

  2. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C (2005) Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2(3):A17

    PubMed  PubMed Central  Google Scholar 

  3. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115(1):116–126

    Article  PubMed  Google Scholar 

  4. MARINA Study Group, Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431

    Article  Google Scholar 

  5. ANCHOR Study Group; Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Lanchulev T (2006) Ranibizumab versus Verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65

    Google Scholar 

  6. Smiddy WE (2009) Economic implications of current age-related macular degeneration treatments. Ophthalmology 116(3):481–487

    Article  PubMed  Google Scholar 

  7. Real JP, Tártara I, Allemandi D, Granero G, Palma SD (2011) Tratamiento de la degeneración macular asociada a la edad (DMAE). Atención Farmacéutica. (European Journal of Clinical Pharmacy) Barcelona: rasgo editorial. 13(3):160–171

  8. Stewart MW (2015) Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing? J Clin Med 4:1079–1101

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Monés J, Biarnés M, Trindade F, Casaroli-Marano R (2012) FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol 250(12):1737–1744

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, Tuomi L, Ehrlich JS, Rubio RG, Campochiaro PA (2014) Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology 21(11):2237–2246

    Article  Google Scholar 

  11. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118(4):663–671

    Article  PubMed  Google Scholar 

  12. Rebasa P (2005) Basic concepts in survival analysis. Cirugía Española 78(4):222–230

    Article  PubMed  Google Scholar 

  13. Moraleda A, Villalba CM (2013) Modelado y Simulación de Eventos Discretos (ebook), 1ra edicion edn. Uned. Universidad Nacional de Educacion a Distancia, España

    Google Scholar 

  14. ARRIBALZAGA EB (2007) Interpretación de las curvas de supervivencia. Rev Chil Cir 59(1):75–83. https://doi.org/10.4067/S0718-40262007000100013

    Article  Google Scholar 

  15. Cox C, Chu H, Schneider MF, Muñoz A (2007) Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med 26(23):4352–4374

    Article  PubMed  Google Scholar 

  16. Arroyo I, Bravo LC, Llinas H, Munoz FL (2014) Distribuciones Poisson y Gamma: Una Discreta y Continua Relación. Prospect. [online], 12(1):99–107. http://www.scielo.org.co/pdf/prosp/v12n1/v12n1a12.pdf

  17. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; http://handbook-5-1.cochrane.org. Accessed 6 Jul 2015

  18. Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, Henschien H, Fossen K, Markovic S, Pedersen TR, Sandvik L, Bragadóttir R (2015) Ranibizumab or Bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results. Ophthalmology 123(1):51–59

    Article  PubMed  Google Scholar 

  19. IVAN study investigators [IVAN], Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258–1267

    Article  CAS  Google Scholar 

  20. Hörster R, Ristau T, Sadda SR, Liakopoulos S (2011) Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249(5):645–652

    Article  PubMed  CAS  Google Scholar 

  21. Mantel I, Deli A, Iglesias K, Ambresin A (2013) Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251(3):697–704

    Article  PubMed  CAS  Google Scholar 

  22. Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S (2012) Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Ophthalmology 10:2082–2086

    Article  Google Scholar 

  23. Cohen SY, Dubois L, Tadayoni R et al (2009) Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409–413

    Article  PubMed  CAS  Google Scholar 

  24. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364(20):1897–1908

    Article  PubMed  CAS  Google Scholar 

  25. Real JP, Granero GE, De Santis MO, Juarez CP, Palma SD, Kelly SP, Luna JD (2015) Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol 253(11):1859–1865

    Article  PubMed  Google Scholar 

  26. Barquet A, Monés J (2012) New treatment protocols and follow-up in patients with exudative age-related macular degeneration. Arch Soc Esp Oftalmol 87(Suppl 1):10–17

    Article  Google Scholar 

  27. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 17(11):2134–2140

    Article  Google Scholar 

  28. Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, Fajnkuchen F, Tadayoni R (2011) Inject and extend dosing versus dosing as needed: a comparative retrospective study of Ranibizumab in exudative age-related macular degeneration. Retina 3:26–30

    Article  Google Scholar 

  29. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150(3):315–324

    Article  PubMed  CAS  Google Scholar 

  30. Magdelaine-Beuzelin C, Pinault C, Paintaud G, Watier H (2010) Therapeutic antibodies in ophthalmology: old is new again. MAbs 2(2):176–180

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000, Córdoba, Argentina

    J. P. Real & S. D. Palma

  2. Vitreo-Retinal Department, Centro Privado de Ojos Romagosa SA - Fundación VER, Deán Funes 429/432, Córdoba, Argentina

    J. D Luna

Authors
  1. J. P. Real
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. D Luna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. D. Palma
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.

Ethical approval

For this type of study, formal consent is not required

Electronic supplementary material

ESM 1

(DOCX 54 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Real, J.P., Luna, J.D. & Palma, S.D. The reactivation time in the treatment of AMD: a forgotten key parameter?. Graefes Arch Clin Exp Ophthalmol 256, 1079–1087 (2018). https://doi.org/10.1007/s00417-018-3974-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-018-3974-0

Keywords

Search

Navigation